AVITA Medical (RCEL) Net Income towards Common Stockholders (2018 - 2025)
AVITA Medical (RCEL) posted Net Income towards Common Stockholders of -$1.4 million for Q4 2025, up 89.32% on a QoQ basis from -$13.2 million in Q3 2025, and up 87.83% year-over-year from -$750153.3 in Q4 2024.
AVITA Medical (RCEL) Net Income towards Common Stockholders (2018 - 2025) Analysis & Trends
AVITA Medical's Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$1.4 million for Q4 2025.
- Quarterly Net Income towards Common Stockholders rose 87.83% year-over-year to -$1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$38.4 million (up 37.94% YoY) and the FY2025 annual result came in at -$38.4 million, up 37.94% from the prior year.
- Net Income towards Common Stockholders was -$1.4 million for Q4 2025 at AVITA Medical, up from -$13.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $21.4 million in Q4 2022 and bottomed at -$18.7 million in Q1 2024.
- A 5-year average of -$9.0 million and a median of -$10.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders plunged 133.0% — and 2025, when it surged 87.83%.
- AVITA Medical's Net Income towards Common Stockholders stood at -$16.7 million in 2021, then soared by 228.49% to $21.4 million in 2022, then plunged by 133.0% to -$7.1 million in 2023, then sank by 63.85% to -$11.6 million in 2024, then jumped by 87.83% to -$1.4 million in 2025.
- Business Quant data shows RCEL's Net Income towards Common Stockholders at -$1.4 million in Q4 2025, -$13.2 million in Q3 2025, and -$9.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.08 Bn | 175.79 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.71 Bn | 125.83 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 108.79 Bn | 99.57 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 68.41 Bn | 66.96 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.34 Bn | 44.67 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn | 411.00 Mn |
| 7 | Dexcom | 28.34 Bn | 27.22 Bn | 750.30 Mn | 199.50 Mn |
| 8 | Smith & Nephew | 26.87 Bn | 26.29 Bn | - | - |
| 9 | Koninklijke Philips | 25.43 Bn | 22.31 Bn | 2.07 Bn | 176.78 Mn |
| 10 | AVITA Medical | 132.62 Mn | 116.28 Mn | 14.31 Mn | -1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.41 Mn |
| Sep 30, 2025 | -13.19 Mn |
| Jun 30, 2025 | -9.92 Mn |
| Mar 31, 2025 | -13.86 Mn |
| Dec 31, 2024 | -11.58 Mn |
| Sep 30, 2024 | -16.21 Mn |
| Jun 30, 2024 | -15.39 Mn |
| Mar 31, 2024 | -18.66 Mn |
| Dec 31, 2023 | -7.07 Mn |
| Sep 30, 2023 | -8.71 Mn |
| Jun 30, 2023 | -10.38 Mn |
| Mar 31, 2023 | -9.22 Mn |
| Dec 31, 2022 | 21.41 Mn |
| Sep 30, 2022 | -5.59 Mn |
| Mar 31, 2022 | -9.46 Mn |
| Sep 30, 2021 | -16.66 Mn |
| Jun 30, 2021 | -10.72 Mn |
| Mar 31, 2021 | -6.00 Mn |
| Dec 31, 2020 | -5.64 Mn |
| Sep 30, 2020 | -10.23 Mn |